Faisal Sukhtian Net Worth

The estimated Net Worth of Faisal Ghiath Sukhtian is at least 478 千$ dollars as of 7 October 2022. Mr. Sukhtian owns over 30,000 units of Outlook Therapeutics Inc stock worth over 478,040$ and over the last 7 years he sold OTLK stock worth over 0$. In addition, he makes 0$ as Independent Director at Outlook Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Sukhtian OTLK stock SEC Form 4 insiders trading

Faisal has made over 4 trades of the Outlook Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 30,000 units of OTLK stock worth 38,700$ on 7 October 2022.

The largest trade he's ever made was buying 30,000 units of Outlook Therapeutics Inc stock on 7 October 2022 worth over 38,700$. On average, Faisal trades about 4,250 units every 47 days since 2017. As of 7 October 2022 he still owns at least 68,000 units of Outlook Therapeutics Inc stock.

You can see the complete history of Mr. Sukhtian stock trades at the bottom of the page.

Faisal Sukhtian biography

Faisal Ghiath Sukhtian serves as Independent Director of the Company. He has served as a Director of GMS Tenshi Holdings Pte. Limited since 2011, and an Executive Director of GMS Holdings, a diversified investment company, since 2008. In addition to managing operations of GMS Holdings, Mr. Sukhtian oversees a number of investments within the GMS Holdings portfolio and serves as a director of GMS Holdings’ board of directors. From 2008 to 2011, Mr. Sukhtian served as Executive Director of Munir Sukhtian International. From 2010 to 2011, he served as Managing Director of Agri Sciences Ltd., an agrochemicals manufacturing business based in Turkey. Mr. Sukhtian has served as a member of the board of directors of Expert Petroleum, an oilfield services company based in Romania, since 2008, Agri Sciences since 2010, M.S Pharma, a leading MENA based branded pharmaceutical generics company, since 2011 and Stelis Biopharma Private Limited, a biotherapeutic and biosimilar developer and manufacturer based in India, since 2015. Mr. Sukhtian previously served as a member of the board of directors of Alvogen, a multinational generics pharmaceutical company based in the United States, from 2008 to 2014 and Waterloo Industries, Inc., a manufacturer of tool storage based in the United States, from 2015 to 2017. Prior to joining GMS Holdings, Mr. Sukhtian worked at JP Morgan, in New York, where he worked primarily on mergers and acquisitions, debt and equity transactions serving clients in the industrials and transportation industries. Mr. Sukhtian received an M.B.A. from Columbia Business School and a B.S. in International Economics from Georgetown University’s School of Foreign Service. Mr. Sukhtian was appointed to fill a vacancy on the Board, and was designated for such vacancy by GMS Tenshi Holdings Pte. Limited pursuant to the Investor Rights Agreement by and between Oncobiologics, Inc. and GMS Tenshi Holdings Pte. Limited dated September 11, 2017.

How old is Faisal Sukhtian?

Faisal Sukhtian is 35, he's been the Independent Director of Outlook Therapeutics Inc since 2017. There are 13 older and no younger executives at Outlook Therapeutics Inc. The oldest executive at Outlook Therapeutics Inc is Ralph H. Thurman, 72, who is the Independent Exec. Chairman.

What's Faisal Sukhtian's mailing address?

Faisal's mailing address filed with the SEC is C/O OUTLOOK THERAPEUTICS, INC., 485 ROUTE 1 SOUTH, BUILDING F, SUITE 320, ISELIN, NJ, 08830.

Insiders trading at Outlook Therapeutics Inc

Over the last 6 years, insiders at Outlook Therapeutics Inc have traded over 1,453,842$ worth of Outlook Therapeutics Inc stock and bought 29,698,365 units worth 33,411,235$ . The most active insiders traders include Pte Ltd.Pillai Arun Kumar S...、Ghiath M.Gms Ventures & Inv...、Ventures Llc Syntone. On average, Outlook Therapeutics Inc executives and independent directors trade stock every 43 days with the average trade being worth of 11,985,869$. The most recent stock trade was executed by Ventures Llc Syntone on 15 April 2024, trading 714,286 units of OTLK stock currently worth 5,021,431$.

What does Outlook Therapeutics Inc do?

overview oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mabs), in the therapeutic areas of immunology and oncology. our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company. we have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our biosymphony™ platform. oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mab biosimilars. pipeline oncobiologics is actively working on eight biosimilar candidates. the company’s most advanced assets, ons-3010 (a biosimilar of humira®) and ons-1045 (a biosimilar of avastin®) have both successfully completed phase i trials and phase 3 t

Complete history of Mr. Sukhtian stock trades at Outlook Therapeutics Inc

Outlook Therapeutics Inc executives and stock owners

Outlook Therapeutics Inc executives and other stock owners filed with the SEC include:

• Lawrence Kenyon,
  President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
• Lawrence A. Kenyon CPA,
  Exec. VP, CFO, Treasurer, Company Sec. & Director
• C. Russell Trenary III,
  Pres, CEO & Director
• Randy Thurman,
  Executive Chairman of the Board
• Terry Dagnon,
  Chief Operations Officer
• Jeffrey Evanson,
  Chief Commercial Officer
• Ralph H. Thurman,
  Independent Exec. Chairman
• Jeremy Feffer,
  IR Contact Officer
• Faisal Sukhtian,
  Independent Director
• Kurt Hilzinger,
  Independent Director
• Yezan Haddadin,
  Independent Director
• Andong Huang,
  Director
• Julian Gangolli,
  Director
• Gerd Auffarth,
  Director
• Jeff Evanson,
  Chief Commercial Officer
• Terry Dagnon,
  Chief Operating Officer
• Alicia Tozier,
  Sr. VP, Marketing & Market Access
• Joel Prieve,
  Sr. VP of Commercial Operations
• Elizabeth A. Yamashita,
  Advisor
• Dr. Balu N. Balasubramanian,
  Advisor
• Rick Gregory,
  Director of Marketing & Communications
• C Russell Iii Trenary,
  CEO AND PRESIDENT
• Pte Ltd.Pillai Arun Kumar S...,
  
• Ghiath M.Gms Ventures & Inv...,
  
• Joe Thomas,
  Director
• Pte Ltd. Bio Lexis,
  10% owner
• Faisal Ghiath Gms Ventures ...,
  
• Arun Kumar Pillai,
  Director
• Ventures Llc Syntone,
  
• Julia A Haller,